Merck & Company, Inc. vs TransMedics Group, Inc. — Stock Comparison

MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
vs
TMDX
TransMedics Group, Inc.
$100.01
▼ 0.77%
Q·Score Winner
TransMedics Group, Inc.
TMDX8.8/10vs 6.7/10

Q·Score Breakdown

6.7
Neutral
Overall
8.8
Very Bullish
6.2
Quality
9.3
7
Health
8.2
6.2
Growth
10
7.2
Valuation
8.4
7.1
Sentiment
7.8
MRK

Forward P/E of 11.5× is low relative to sector peers.

TMDX

Earnings growing 1188% year-over-year on 32% revenue growth.

Analyst Consensus

BUY
Target $129.74 (+15.7%)
27 analysts
BUY
Target $156.00 (+56.0%)
10 analysts

Fundamentals

MRK
TMDX
31.5×
Trailing P/E
20.5×
11.5×
Forward P/E
27.2×
13.6%
Profit Margin
31.4%
76.6%
Gross Margin
59.9%
ROE
54.2%
4.9%
Revenue Growth
32.2%
Earnings Growth
1188.1%
0.28
Beta
2.08
Price / Book
$277.0B
Market Cap
$3.5B
$73 – $125
52-Week Range
$90 – $156

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →